Background
Non-coding RNA (ncRNA) is a general term for RNAs that lacks protein-coding functionality. With recent developments in highthroughput sequencing techniques, increasing numbers of ncRNAs have been discovered, and are now categorized into two classes, depending on the transcript length. One ncRNA class is up to 200 nucleotides in length and includes microRNAs (miRNAs), small interfering RNAs (siRNAs), and small nuclear RNAs (snRNAs) [1, 2] . Another ncRNA class is composed of long non-coding RNAs (lncRNAs) that contain 200 or more nucleotides in length [3] . Previously, lncRNAs were unknown entities within the genome [4, 5] . Recently, although only a few lncRNAs have been discovered, they are now thought to play critical regulatory roles in physiological and pathological processes, including in cancer [6, 7] . Recently, increasing numbers of studies on the roles of lncRNA have shown that changes in expression levels of lncRNAs have been found in several types of malignant tumors, indicating a role for lncRNAs in the development and progression of malignancy. Therefore, studies of lncRNA expression levels might have a future role as diagnostic or prognostic biomarkers in human cancer [8, 9] . The lncRNAs that have been most commonly associated with cancer-related pathways have been studied in human tumors and have been found to function as regulators via several molecular mechanisms [10] . However, these studies on the role of lncRNAs in are still at an early stage, and many of the potential mechanisms and clinical significance of lncRNAs remain unclear and require further studies.
Worldwide, hepatocellular carcinoma (HCC) is one of the most common malignant tumors [11] . Recently published studies have shown that lncRNAs play a regulatory function in the onset and development of HCC, providing a new direction for the clinical diagnosis and treatment of this cancer [12, 13] . Currently, there are several lncRNAs that have been found to be abnormally expressed in HCC. These lncRNAs influence the onset, development, invasion, metastasis, and recurrence of HCC by participating in multiple tumor-related pathways [14] . Considering the important molecular mechanisms of lncRNA in the onset and progression of HCC, the potential role of lncRNA in clinical practice has gained research interest. Recently, Qu et al. undertook a meta-analysis that included data from 27 published and found that the upregulation of lncRNA was associated with a reduced overall survival in HCC [15] . Although some studies have reported that lncRNAs play critical functions as oncogenes or tumor suppressor genes, the lncRNAs studied thus far represent only a small fraction of the lncRNAs defined in Gene Expression Profiling Interactive Analysis (GEPIA) [16] . Therefore, the investigation of new lncRNAs in HCC is an important area of research.
In this study, lncRNAs that were abnormally expressed in HCC were identified from liver hepatocellular carcinoma (LIHC) data in The Cancer Genome Atlas (TCGA) database (http:// cancergenome.nih.gov/). The lncRNA, LINC0065 was selected as it had not been previously studied in HCC. The aim of this study was to investigate the expression of the lncRNA, LINC0065 gene and the cell cycle in HCC using database analysis including The Cancer Genome Atlas (TCGA), the Gene Expression Omnibus (GEO), and quantitative real-time polymerase chain reaction (qPCR), and its relationship to clinical parameters, and its prognostic value from cases at our hospital. Genes related to LINC00665 were determined through the Atlas of Noncoding RNAs in Cancer (TANRIC), and Multi Experiment Matrix (MEM) databases and the relationship between LINC00665 and cell cycle pathways were investigated using bioinformatics methodology.
Material and Methods
Data extraction from The Cancer Genome Atlas (TCGA) database and analysis of differentially expressed long non-coding RNAs (lncRNAs)
From the differentially expressed long non-coding RNAs (lncRNAs) found in The Cancer Genome Atlas (TCGA), the long intergenic non-protein coding RNA 665 (LINC00665) gene was selected for this study. The log 2 transcripts per million (TPM+1) algorithm for TCGA data developed by Gene Expression Profiling Interactive Analysis (GEPIA) (http://gepia.cancer-pku.cn/) was applied to study the expression of LINC00665 in hepatocellular carcinoma (HCC) tissue and in normal adjacent liver tissue [16] .
Expression of LINC00665 using other open databases
The relevant lncRNA chip or sequencing data for HCC from Gene Expression Omnibus (GEO) (https://www.ncbi.nlm.nih. gov/geo/), ArrayExpress (http://www.ebi.ac.uk/arrayexpress/), and Oncomine (https://www.oncomine.org/resource/login.html) databases were collected. The search terms used were: malignant OR cancer OR tumor OR neoplasia OR carcinoma AND hepatocellular OR liver OR hepatic OR HCC. All relevant expression data and clinical parameters related to LINC00665 were extracted.
Data from quantitative real-time polymerase chain reaction (qPCR) examination of clinical samples HCC and corresponding adjacent normal liver tissue samples from 39 cases receiving hepatectomies at the First Affiliated Hospital of Guangxi Medical University, between January 2012 to August 2013 were selected. Patients were excluded from the study if they were receiving adjuvant chemotherapy or radiotherapy. The HCC tumors and adjacent normal liver tissue were diagnosed independently by two pathologists (Yuyan Pang and Gang Chen). Control adjacent normal liver specimens were collected from sites at least 2 cm from the surgical margin; no tumor cells were found in the control specimens on histological examination. All tissue samples were fixed in 10% formaldehyde and subjected to routine paraffin embedding, and tissue sectioning. This study was approved by the local Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. All patients signed informed consents to participate in the study.
RNA extraction and quantitative real-time polymerase chain reaction (qPCR)
Total RNA was extracted from 39 tissue samples of HCC, and paired adjacent normal liver tissues, using the Qiagen RNeasy FFPE Kit (Qiagen, Netherlands) to purify total RNA from formalin-fixed, paraffin-embedded tissue sections, according to the manufacturer's protocol [17, 18] . Quantification of LINC00665 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was performed using the PCR7900 (Applied Biosystems, Amsterdam, Netherlands).
The sequences of the LINC00665 primers used were as follows: 5'-AGCACCCCTAGTGTCAGTCA-3' (forward), 5'-TGGTCTCTAGGGAGGCAGAA-3' (reverse). For GAPDH (internal control), the primers were as follows: 5'-AGTGGCAAAGTGGAGATT-3' (forward), 5'-GTGGAGTCATACTGGAACA-3' (reverse).
Expression levels of LINC00665 were evaluated using the 2 -DCt method.
Statistical analysis
Data were analyzed using SPSS version 24.0 (Chicago, IL, USA). GraphPad Prism 7 software (GraphPad Software, San Diego, CA, USA) was used to plot data. Data were expressed as the mean ± standard deviation (SD). Independent sample t-tests were used to analyze the expressions of LINC00665 and related genes in HCC and adjacent normal liver tissues. Spearman's correlation test was used to analyze the relationship between LINC00665 and the clinicopathological features of patients with HCC.
The expression of LINC00665 and related genes were demonstrated by scatter plots and box plots. One-way analysis of variance (ANOVA) was used to process and demonstrate the differences in data from three or more groups. The total standardized mean difference (SMD) with 95% confidence interval (CI) and summary receiver operating characteristic (ROC) curves were calculated with STATA version 12.0 (StataCorp, College Station, TX, USA). When SMD was >0 and the 95% CI did not include 0, the expression of LINC00665 in tumors was considered to be overexpressed when compared with that in normal adjacent liver tissue.
To test the performance of LINC00665 expression in the differentiation between HCC and normal liver tissues, SPSS was used to construct the ROC curve for each dataset and to calculate the area under the ROC curve (AUC). Meta-Disc1.4 software was used to evaluate the combined effect, sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic score (DS), and diagnostic odds ratio (DOR). The I 2 test was applied to examine the heterogeneity between studies; when the P value was <0.05 or when the I 2 value was >50%, then heterogeneity is considered to exist between studies. A random-effects model was selected to combine data; otherwise, a fixed-effects model was implemented. The correlation between the expressions of LINC00665 and related hub genes was analyzed using Pearson's correlation analysis. For all statistical analysis, two-tailed analysis of differences was considered to be statistically significant with a P-value <0.05.
Potential genes that correlated to LINC00665 in HCC
Potential target genes of LINC00665 were predicted through The Atlas of Noncoding RNAs in Cancer (TANRIC) and MEM databases [19, 20] . To obtain a more reliable pathway analysis and a correlated gene network, genes predicted by both TANRIC and the Multi Experiment Matrix (MEM) databases were identified.
Analysis of associated gene-enriched pathways and their functions
To study the potential molecular mechanisms of LINC00665-associated genes, the Web-based Gene Set Analysis Toolkit (WebGestalt) was used (http://www.webgestalt.org/option. php) for Gene Ontology (GO) analysis, the Kyoto Encyclopedia of Genes and Genomes (KEGG), Protein Analysis Through Evolutionary Relationships (PANTHER), and the Reactome pathway analysis databases were used [21] . The results were considered to be statistically significant when the false discovery rate (FDR) was <0.05. GOview (http://www.webgestalt. org/GOView/) was used to visualize Gene Ontology (GO) pathways [22] . R3.4.1 with the ggplot2 package was used to visualize pathway annotations from KEGG, PANTHER, and Reactome.
Construction of a protein-protein interaction (PPI) network and confirmation of hub genes
To identify the connections and interactions between overlapping genes, version 10.5 of STRING (http://www.string-db. org) was applied to construct the Protein-Protein Interaction (PPI) network for overlapping correlating genes [23] . Genes with combined scores >0.9 were obtained. Those genes that intersected with the gene enriched in the first KEGG pathway were identified as the hub genes of LINC00665.
Results
Expression of the long intergenic non-protein coding RNA 665 (LINC00665) gene in hepatocellular carcinoma (HCC) based on database analysis
Prior to this study, using The Cancer Genome Atlas (TCGA), RNASeq-based transcriptome data was obtained for the LIHC gene and analyzed using the DESeq package with the R-language. The long non-coding RNAs (lncRNAs) differentially expressed in hepatocellular carcinoma (HCC) were obtained. The long intergenic non-protein coding RNA 665 (LINC00665) gene, which had not previously appeared in the published literature, was selected as the subject of this study (Figure 1 ).
Data on LINC00665 from TCGA that could be used for expression analysis were extracted. The results of data analysis indicated that among the 370 identified cases of HCC the expression of LINC00665 was significantly increased in HCC tumor tissues compared with the paired normal liver tissues Figure 3B ). From several online databases, including Gene Expression Omnibus (GEO), ArrayExpress, and Oncomine, one chip was obtained from the GEO database that was expressed in both HCC and matched normal liver tissues, which was the GSE54236 chip from the GEO database (Agilent-014850 Whole Human Genome Microarray). However, in the GSE54236 chip, the expression levels of LINC00665 in HCC and normal adjacent liver tissues were not significantly different (5.7859±0.9652 vs. 5.8175±1.0390; FC=0.9946) (P=0.842) ( Figure 2C ). ROC curve analysis showed an AUC of 0.519 (P=0.682, 95% CI: 0.439-0.598) ( Figure 2D ).
The quantitative real-time polymerase chain reaction (qPCR) was used to evaluate the expression of LINC00665 in 39 pairs of HCC tissues and normal adjacent liver tissues from our hospital. The results showed that the expression of LINC00665 in HCC samples was significantly increased in HCC tumor tissues compared with the paired normal liver tissues (3.1972±1 Figure 2E ). ROC curve analysis showed an AUC of 0.709 (P<0.001; 95% CI: 0.596-0.807) ( Figure 2F ). To obtain Di erentially expressed LINC00665
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The cancer genome atlas results from a comprehensive analysis of LINC00665 expression representing different databases and study methods, data were combined, and meta-analysis of data from TCGA, GEO, and in-house qPCR was undertaken.
Using the random-effects model, the pooled total standardized mean difference (SMD) of LINC00665 was 0.50 (95% CI: -0.06-1.05; P=0.078; I 2 =86.8%; P=0.001) ( Figure 4A ). The results of a meta-analysis of diagnostic tests showed that in the summary receiver operating characteristic (SROC) curves, the AUC was 0.614 (95% CI: 0.525-0.702) ( Figure 4B ). The pooled sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic score (DS), and diagnostic odds ratio (DOR) of LINC00665 in these studies were 0.55 (95% CI: 0.51-0.60), 0.53 (95% CI: 0.45-0.61), 2.57 (95% CI: 0.32-20.48), 0.85 (95% CI: 0.37-1.97), and 17.84 (95% CI: 5.46-58.34), respectively ( Figure 5A-5E ). Due to heterogeneity, GSE54236 data were eliminated. The results based on other combined data indicated that LINC00665 was highly expressed in HCC (SMD=0.75; 95% CI: 0.50-1.00; P<0.001; I 2 =0, P=0.503) ( Figure 4C ). In conclusion, LINC00665 was highly expressed in HCC tissues, but this finding was obtained from only two studies that included a total of 498 cases.
Clinical significance of LINC00665 expression in the development and prognosis of HCC Considering its possible carcinogenic function in HCC, LINC00665 may facilitate the development of HCC. For this reason, the expression of LINC00665 against various parameters in clinical cases was analyzed, as well as the correlation of LINC00665 expression with clinical progress. The results of analysis based on the TCGA database indicated that LINC00665 was correlated to gender, histological grade of HCC, tumor stage, and the presence of vascular invasion (Table 1) . For gender, tumor stage, tumor grade, and the presence of vascular invasion, the results of independent sample t-tests and Spearman's correlation tests showed that the expression of LINC00665 was significantly greater in women compared with men (7.8508±2.2100 vs. 6 Because other databases did not provide usable data on clinical parameters in HCC, qPCR was also used to study the expression of LINC00665 in 39 patients with HCC in our hospital, with different clinical subgroups. Differential expression of LINC00665 in subgroups was not detected (Table 2) ; a possible reason for this finding was the small number of cases in the study.
To investigate the effect of the increased expression of LINC00665 on the prognosis and survival of patients with HCC, the cases of HCC from TCGA were split into high-expression and low-expression groups, based on the median level of LINC00665 expression. In this study, the Kaplan-Meier method was used for statistical analysis. The results of survival curve analysis indicated that the median overall survival (OS) for the high-expression group was 1,397 days; the median OS for the low-expression group was 2,116 days. The hazard ratio (HR) of OS was 1.477 (95% CI: 1.046-2.086). These results showed that the OS of patients with HCC with LINC00665 overexpression were shorter than those of patients with LINC00665 expressed at low levels (log-rank, P=0.027) ( Figure 8A ). However, there was no statistically significant alteration in the diseasefree survival (DFS) of patients with high versus low expression levels of LINC00665 (log-rank P=0.364; HR=1.129; 95% CI: 0.8687-1.468) ( Figure 8B) . Therefore, the ability of LINC00665 to predict DFS was limited.
LINC00665-correlated genes and analysis of geneenrichment pathways
A total of 1,277 genes that correlated with LINC00665 were obtained from The Atlas of Noncoding RNAs in Cancer (TANRIC) website. Additionally, 4,296 correlated genes were obtained from the Multi Experiment Matrix (MEM) database. Based on genes obtained from the above databases, 469 overlapped genes were obtained ( Figure 9A ). The WebGestalt (WEB-based GEne SeT AnaLysis Toolkit) analysis was used to confirm Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Protein Analysis Through Evolutionary Relationships (PANTHER), and Reactome pathways. GO: 0051301-Cell division (P=2.28, E-23) (Table 3 ) (Figure 9B ), GO: 0005654-nucleoplasm (P=3.47, E-29) (Table 3 ) (Figure 9C ), and GO: 0003676-nucleic acid binding (P=6.39, E-19) (Table 3 ) ( Figure 9D ) were the first GO annotated pathways for biological process (BP), cellular component (CC), and molecular function (MF).
The first pathways in the PANTHER and Reactome databases were P00022: General transcription by RNA polymerase I (P=3.48, E-01) (Table 4) ( Figure 10B ) and R-has-1640170: the Cell Cycle pathway (P=0.00, E+00) (Table 4) ( Figure 10C ). KEGG (Figure 11 ).
Construction of the protein-protein interaction (PPI) network and the hub genes
Using version 10.5 of the STRING database, a functional protein network containing the above 469 genes was analyzed. Through the constructed protein-protein interaction (PPI) network, the 30 genes with the most connections were obtained ( Figure 12 ). Genes with combined scores greater than 0.999 are illustrated in Figure 13 , using Cytoscape version 3.5.1. The cell cycle pathways described above play critical functions in the growth of tumor cells. Therefore, the overlap between the top 30 genes connected within the PPI network and 24 genes in the cell cycle pathway were reviewed, and ten overlapping genes were identified, which were, in our opinion, the core or hub genes for the facilitation of LINC00665 in tumor growth and development. These ten core or hub genes were CDK1, BUB1B, BUB1, PLK1, CCNB2, CCNB1, CDC20, ESPL1, MAD2L1, and CCNA2.
Verification of the relationship between LINC00665 and the ten core or hub genes
Using TCGA database, verification was performed on the relationship between LINC00665 and the expression of the ten identified hub genes in HCC tissues. Based on independent sample t-tests, the expression of the ten hub genes, CDCA5  SKA1  ERCC6L  NUF2  CENPO  CENPM  CENPI  CENPH  XPO1  KIF11  TOP2A  ESPL1  NUP43  NUP107  CCNA2  CENPA  BIRC5  NDC80  KIF2C  CDCA8  BUB1B  MAD2L1  BUB1  CDC20  CCNB2  AURKB  PLK1  CCNB1  CDK1   10  20  30  40 (Figures 14, 15) . A principal component analysis (PCA) was performed on these ten hub genes using GEPIA. A threedimensional (3-D) plot confirmed that these ten genes had the greatest potentential as biomarkers for HCC ( Figure 16 ).
Discussion
In this study, differential investigation of long non-coding RNA (lncRNA) was based on sequencing data from patients with hepatocellular carcinoma (HCC) provided by the open database, The Cancer Genome Atlas (TCGA). This study is the first to report that the expression of long intergenic non-protein coding RNA 665 (LINC00665) gene was significantly increased in HCC tissues compared with adjacent normal tissues. Confirmation of the findings was performed with the use of other online databases and using the findings from quantitative real-time polymerase chain reaction (qPCR) results in cases from our hospital.
In this study, expression of LINC00665 was significantly upregulated in HCC tumor tissue from patients with HCC and was correlated with certain clinical and pathological features, including poor tumor differentiation (grade), a high TNM score (stage), and the presence of vascular invasion, which is a requirement for tumor metastasis. As these clinical parameters can reflect the clinical prognosis in HCC, LINC00665 may function as an oncogene in the initiation and progression of HCC. This view is supported by the finding from this study that patients with HCC who had highly upregulated LINC00665 had a worse overall survival (OS).
In this study, the association between malignant biological behavior of HCC and upregulation of LINC00665 were studied in terms of facilitating the onset and development of HCC. Through using bioinformatics analysis, increased expression of LINC00665 was shown to facilitate the development of HCC by regulating a series of genes that trigger changes in the cell cycle pathways. The results of this study indicated that upregulation of LINC00665 might be important in the onset and development of HCC. Therefore, measurement of LINC00665 expression may have important future clinical applications.
The primary aim of this study was to explore the expression of LINC00665 in HCC, by performing an analysis of TCGA data and the study findings showed that the LINC00665 was significantly overexpressed in HCC tissues when compared with the normal adjacent liver tissues. Other open databases such as Gene Expression Omnibus (GEO), Arrayexpres, and Oncomine, as well as quantitative real-time polymerase chain reaction (qPCR) data from cases at our hospital, were used for confirmation. Comprehensive results were obtained via meta-analysis. The overall total standardized mean difference (SMD) was 0.75 (95% CI: 0.50-1.00). These results indicated that there was a trend of increasing LINC00665 expression as HCC progressed. Although these findings require further examination through an independent cohort study and other methods, LINC00665 might also participate in the onset of HCC as a tumor-promoting factor.
The most important finding in this study was the close correlation between the increased expression of LINC00665 and the presence of tumor cell vascular invasion, which also supports the possibility that LINC00665 can also be a potential predictive biomarker for the progress of HCC. For histological grades 3-4, clinical stages III-IV, and for patients who had HCC with the presence of vascular invasion, LINC00665 expression was significantly greater than in patients with histological grades 1-2, stages I-II, and patients without the presence of vascular invasion. This study found that the OS of HCC patients with high expression levels of LINC00665 was less than that of patients with low expression levels of LINC00665 (HR=1.4, P=0.07). However, this trend requires further confirmation with a larger number of study participants. The findings from this study indicate that expression of LINC00665 is closely correlated to the development of HCC, especially vascular invasion. However, due to the lack of reports on LINC00665 in the literature, the molecular mechanism of LINC00665 in the onset and development of HCC remains unknown.
Therefore, in this study, an attempt was made to predict the functional mechanism of LINC00665 in HCC using bioinformatics. We first obtained 469 genes that were correlated to LINC00665 through The Atlas of Noncoding RNAs in Cancer (TANRIC) and Multi Experiment Matrix (MEM) databases. Subsequently, we performed Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Protein Analysis Through Evolutionary Relationships (PANTHER), Reactome, and protein-protein interaction (PPI) analysis on these 469 genes. The results indicated that these genes function in multiple biological processes and have multiple molecular functions, among which cell cycle pathways had the most significant gene enrichment, as indicated by KEGG analysis. The cell cycle is controlled by multiple mechanisms to ensure the accurate division of cells [24, 25] . A disturbance in cell cycle pathways could lead to cell cycle arrest and could be closely correlated to the development and prognosis of tumors [26, 27] . Therefore, it may be argued that LINC00665 could facilitate the generation and development of HCC cells by influencing the cell cycle. To further confirm the target molecule of LINC00665 in the HCC cell cycle, ten genes were identified that overlapped with the genes obtained from PPI analysis and the 24 genes enriched in cell cycle pathways; these ten genes were CDK1, CDC20, ESPL1, CCNB1, MAD2L1, CCNB2, PLK1, BUB1, BUB1B, and CCNA2. Also, these ten genes showed significant overexpression in HCC and were positively correlated with LINC00665. Therefore, it is likely that LINC00665 regulates cell cycle pathways through these ten genes and thereby facilitates the onset and development of HCC.
There have been some previously published reports on the functions of these ten hub genes in HCC. CDK1, a serine/threonine kinase, is a vital regulator of the cell cycle [28, 29] . A study on the knockdown of CDK1 showed that this significantly reduced apoptin-induced HCC cell apoptosis [30] . Li et al. reported a close correlation between overexpression of CDC20 and the development of HCC, as the proliferation of HCC cells was inhibited by interference in the expression of CDC20 [31] . ESPL1 is thought to be an oncogene that is highly expressed in multiple tumors [32, 33] . However, the clinical significance and functional mechanism of ESPL1 have not yet been officially reported in HCC. CCNB1, CCNB2, and CCNA2 belong to the cyclin (CCN) gene family [34, 35] . Cyclins primarily regulate the cell cycle by activating CDK kinase [36] . Previous studies have shown that MAD2L1 is highly expressed in HCC tissues and cells [37] . In HCC, expression of MAD2L1 has also been shown to be closely correlated with the size, stage, and grade of the tumor [38] . PLK1 is a gene that has multiple roles in the cell cycle [39, 40] . The inhibition of PLK1 expression can inhibit the proliferation of HCC cells [41] . Increased expression of the BUB1 gene triggers the onset of several tumors through the pathway of an altered mitotic spindle assembly checkpoint [42] . 
